vibecotamab
Not Tagged
['aml,(-streamline),(-seamless),(-kamloops),(-latamleaders)', 'mds', 'aml,(-streamline),(-seamless),(-kamloops),(-dreamlike)']
congress|#asco23 describes a study evaluating vibecotamab in patients with mrd+aml and mds/cmml post hma failure. the aim of the study is to determine mrd negativity rate post 4 cycles of vibecotamab of 50% and orr of 30% #amlsm 
The AML Hub is an evidence-based online resource on Acute Myeloid Leukemia (AML), for academic researchers and treating clinicians. #leusm